FDA Fine-Tunes Appeals for Device Decision Disputes
Published Date: 11/28/2025
Notice
Summary
The FDA is updating how people can appeal decisions about medical devices and radiological health. This change affects companies and individuals who want to challenge FDA reviews, making the process clearer and easier to follow. Comments on these updates are open until December 29, 2025, with no new fees involved.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Easier CDRH Appeals Submission
If you are a company or individual appealing a Center for Devices and Radiological Health (CDRH) decision, FDA's March 2022 guidance gives recommended formats and content for appeal requests. The guidance (and a March 2020 companion Q&A) says following these recommendations will help the agency consider your request and may facilitate a more timely resolution.
Time Burden for Appeals Submissions
FDA estimates about 75 appeal submissions per year with an average of 8 hours to prepare each request, totaling 600 hours annually. The agency reports an overall increase of 320 hours and 40 responses compared with the prior approval cycle, and states there are no capital costs or operating and maintenance costs tied to this collection.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-21318 — Empowering Local Broadcast TV Stations To Meet Their Public Interest Obligations: Exploring Market Dynamics Between National Programmers and Their Affiliates
The FCC wants to help local TV stations better serve their communities by checking if national programmers and local stations are working well together. They’re asking for ideas on any problems that stop local stations from doing their best public service. Comments are open until December 10, 2025, so broadcasters and viewers can share their thoughts soon!
Next: 2025-21323 — Federal Communications Commission Announces Intent To Dismiss Certain Older Petitions and Applications Related to the Telephone Consumer Protection Act
The FCC plans to dismiss some old requests related to the Telephone Consumer Protection Act, meaning those cases won’t move forward. If you’ve filed one of these, you have until January 12, 2026, to object. This cleanup helps the FCC focus on current issues and could save time and money for everyone involved.